Список проголосовавших за комментарий " <br/> <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="articleColumn">On The Wires<ul><li>Southwest Airlines Co. (<strong>LUV</strong>) is announcing plans to bring its iconic brand, low fares, and exceptional Customer Service to Cincinnati and Grand Cayman (subject to requisite governmental approvals) beginning June 4, 2017. «Bringing Southwest to Cincinnati not only answers a call from our new community and corporate partners for key nonstop service and broad network access with more affordable fares but also now gives our more than 110 million annual Customers access to a full complement of the top 50 markets across the contiguous 48 states,» said Dave Harvey, Southwest Airlines' Managing Director of Business Development. «The addition of Cincinnati is yet another example of how we are connecting communities across the nation with our unmatched schedule and network, full-sized Boeing 737s, and Customer-friendly policies that you'll only find at Southwest.»</li><li>Ruckus Wireless, a part of Brocade (<strong>BRCD</strong>), announced a joint solution with TrackR, a leader in personal item management innovations, that leverages Bluetooth Low Energy (BLE) technology combined with Ruckus ZoneFlex access points (APs) to enhance the indoor and outdoor location services of TrackR's Crowd GPS network. Leveraging existing wireless infrastructure, the new integration provides customers and end users with enhanced asset movement detection in real time and provides more robust security features for enterprise, education, hospitality and large public venues.</li><li>Dotloop (<strong>Z</strong>, <strong>ZG</strong>), a leading platform for simplifying the real estate buying and selling process, today announced that Real (Real Broker LLC) has signed an agreement to bring dotloop services to all of its 800 agents across 18 states. Real is a technology-based brokerage founded by industry veterans and technologists.</li><li>GenVec, Inc. (<strong>GNVC</strong>) announced that it has entered into an exclusive option agreement with Washington University in St. Louis to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting. If the option is exercised, the license will allow broad utilization of technology developed by David T. Curiel, M.D., Ph.D., professor of radiation oncology and Jeffrey Arbeit, M.D., professor of surgery at Washington University School of Medicine. GenVec plans to initially focus on research utilizing the technology to develop treatments for hemophilia.</li><li>Amorsa Therapeutics announced a research, option and license agreement with Janssen Pharmaceuticals (<strong>JNJ</strong>) to develop and commercialize a novel small molecule drug candidate for treatment-resistant depression based on Amorsa's proprietary ketamine analog technology. Amorsa's product candidates are designed to show efficacy as rapidly acting antidepressants with an extended duration of action, possess an attractive side-effect profile, and enable oral dose administration.</li><li>Fate Therapeutics, Inc. (<strong>FATE</strong>), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the first patient has been treated in its PROTECT clinical trial of ProTmune for the prevention of acute graft-versus-host disease (GvHD).</li><li>Scholastic (<strong>SCHL</strong>) will publish an updated edition Fantastic Beasts and Where to Find Them, with a new foreword by J.K. Rowling, writing as Newt Scamander, and a new cover by Headcase Design on March 14, 2017.</li><li>USA Tech (<strong>USAT</strong>) announced it plans to integrate its MORE. loyalty and payroll deduct platform with Apple Pay, for use at up to 300,000 machines nationwide.</li><li>EXACT Sciences (<strong>EXAS</strong>) announced that the Blue Cross Blue Shield Association's 'Evidence Street' recently released a positive review of Cologuard to its members.</li><li>Synthetic Genomics, Inc., entered a research and licensing option agreement with Janssen Vaccines & Prevention of Johnson & Johnson (<strong>JNJ</strong>), to apply Synthetic Genomics' proprietary replicon RNA technology toward the design and development of novel RNA-based medicines for specific infectious diseases.</li><li>Seattle Genetics, Inc. (<strong>SGEN</strong>) announced enrollment of the first patient in a multicenter phase 1 clinical trial of SGN-CD352A for patients with relapsed or refractory multiple myeloma (MM). SGN-CD352A is an investigational CD352-targeted antibody-drug conjugate (ADC) utilizing Seattle Genetics' proprietary ADC technology, an engineered cysteine antibody (EC-mAb) stably linked to a highly potent cytotoxic agent called a pyrrolobenzodiazepine (PBD) dimer.</li><li>Transom Capital Group announced the acquisition of American Driveline Systems (ADS) from American Capital, Ltd. (<strong>ACAS</strong>). ADS is the franchisor of the AAMCO and Cottman Transmission & Total Car Care brands. With nearly 700 franchisee owned and operated locations, AAMCO and Cottman Transmission are the #1 and #2 transmission repair retail chains in North America, respectively, operating in 47 states and three provinces.</li><li>Staples (<strong>SPLS</strong>) appointed Jeff Hall to newly created role of Chief Administrative Officer and Vice Chairman. </li></ul></td> </tr></table>"